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Although a rare entity, chondrosarcoma is the most common malignant tumor of the chest wall. Most patients present with an
enlarging, painful anterior chest wall mass arising from the costochondrosternal junction. CT scan with intravenous contrast
is the gold standard radiographic study for diagnosis and operative planning. Contrary to previous dictum, resection may be
performed in an appropriate surgical candidate based on imaging characteristics or image-guided percutaneous biopsy results;
incisional biopsy is rarely required. The keys to successful treatment are early recognition and radical excision with adequate
margins, as chondrosarcoma is relatively resistant to radiotherapy and conventional cytotoxic chemotherapy. Overall survival
is excellent in most surgical series from experienced centers. Complete excision with widely negative microscopic margins at
the initial operation is of the utmost importance, as local recurrence portends systemic metastasis and eventual tumor-related
mortality. This paper summarizes data from relevant surgical series and thereupon draws conclusions regarding preoperative,
intraoperative, and postoperative management of thoracic chondrosarcoma.
1.Introduction
The thoracic vertebrae, sternum, ribs, and costal cartilages
provide the rigid structure of the thorax. The soft-tissue
constituents include skin, connective tissue, extrathoracic
and intercostal musculature, and pleural mesothelium. In
addition to providing protection for the underlying thoracic
viscera, these structures function harmoniously to support
the physiology of respiration.
Tumors of the chest wall encompass a wide variety
of benign and malignant conditions. The most common
entities are blood-borne rib metastases and direct chest wall
invasion from contiguous lung and breast carcinoma.
Primary chest wall tumors may arise from any of its
soft-tissue, bony,orcartilaginousconstituents.These tumors
are quite rare, with approximately 500 new cases per year
in the United States. As such, most reports in the surgical
literatureconsistofsingle-institutionalstudieswithrelatively
few patients. Soft-tissue tumors account for roughly two-
thirds of cases, while bony and cartilaginous masses account
for approximately one-third. In general, 50–80% of these
tumors are malignant, with increasing rates of malignancy
found as the proportion of soft-tissue tumors increases
within the series [1].
Chondrosarcoma is the most common malignant pri-
mary tumor of both the bony thorax and, in fact, the entire
chest wall [2]. It accounts for nearly one-third of all primary
chest wall tumors. Nevertheless, it is exceedingly rare. As
only 15% of chondrosarcomas arise from the chest wall, the
annual predicted incidence of chest wall chondrosarcoma in
the United States is 60 cases [3].
2.Biology and Histology
Chondrosarcoma is a malignant cartilage-forming tumor of
bone. Interestingly, chondrosarcoma usually arises within
bones formed through ossiﬁcation of a cartilaginous inter-
mediate (endochondral ossiﬁcation) and rarely arise from
bones formed directly from fetal mesenchyme without a2 Sarcoma
cartilaginous intermediate (membranous ossiﬁcation). As
such, chondrosarcomas developmost commonlyin thoracic,
pelvic, and appendicular long bones. Chondrosarcoma most
commonly arises de novo within the medullary cavity of
bone (primary or central) but can result from malignant
transformation of the cartilage cap of a preexisting benign
cartilaginous tumor such as enchondroma or osteochon-
droma (secondary or peripheral) [4].
Histologically, chondrosarcomas are classiﬁed into 3
grades, although grading is subject to interobserver vari-
ability. Grade I tumors are composed predominantly of
extracellular hyaline matrix with chondrocytes displaying
small, dense nuclei (Figure 1). Diﬀerentiation between grade
I chondrosarcoma and benign enchondroma can be diﬃcult.
Grade II tumors contain less chondroid matrix, are increas-
ingly cellular, and may contain mitoses. Grade III tumors
are highly cellular, undiﬀerentiated tumors demonstrating
marked pleomorphism, frequent mitoses, and a mucomyx-
oid matrix [5]. Tumor grade is an important predictor of
local recurrence, systemic metastasis, and survival [4, 5].
3.ClinicalPresentation
Most malignant chest wall tumors present with symptoms.
The vast majority of patients with thoracic chondrosarcoma
present with an enlarging, painful, anterior chest wall mass
arising from eitherthe vicinity ofthe costochondral junction
or the sternum. Less commonly, posterior tumors present in
the paravertebral region, having arisen from the head of a
rib. Asymptomatic tumors detected incidentally by thoracic
imaging are more likely to be benign. In fact, only 6.5% of
96 patients in a retrospective series of patients seen at the
Mayo Clinic over 73 years were without physical ﬁndings
or symptoms [7]. There is a slight male predominance in
most series, with a median age near 50 years. Of 88 chon-
drosarcomas treated at Memorial Sloan-Kettering Cancer
Center, 43% arose in rib, 36% in scapula, 16% in sternum,
and 5% in clavicle [3]. Roughly half of those originating
from rib present in the upper 4 ribs. Approximately 5–10%
of patients present with synchronous systemic metastasis,
most commonly to the lung, liver, and bone. As with
extrathoracic bony and soft-tissue sarcoma, a history of
trauma in the location of the tumor is not uncommon.
Although an association with prior trauma exists, causation
has proven diﬃcult to establish. Similarly, chondrosarcoma
has been reported to arise in previous radiation portals for
metachronous malignancies such as lymphoma and breast
carcinoma, often many years after completion of therapy. As
stated, secondary chondrosarcoma can arise from malignant
degeneration of a benign chondroma or osteochondroma.
4.Diagnosis
Any patient with a suspected or conﬁrmed chest wall mass
should undergo an initial posterior-anterior (PA) and lateral
chest radiograph. However, computed tomography (CT)
scan of the lower neck, thorax, and upper abdomen with
intravenous contrast is the gold standard radiographic study
Figure 1: Photomicrograph of grade I chondrosarcoma, demon-
strating abundant extracellular hyaline matrix and scant cellularity
(Courtesy of Robert S. Beissner MD, PhD, Department of Pathol-
ogy, Scott & White Memorial Hospital and Clinic, Temple, TX,
USA).
for both diagnosis and operative planning, as bone and soft-
tissue windows are available to delineate tumor characteris-
tics and extent of invasion, while lung windows evaluate for
pulmonary metastasis. The characteristic CT appearance of
chondrosarcoma consists of a well-deﬁned, lobulated soft-
tissue mass with foci of chondroid matrix calciﬁcation [8]. A
characteristic ﬂocculentor“popcorn”patternofcalciﬁcation
has been described for chondrosarcoma (Figure 2). Bone
destruction and invasion of overlying soft-tissue may also
exist. Magnetic resonance imaging (MRI) is particularly
useful for deﬁning vascular or neural involvement and
therefore provides complementary information to the CT
scan for tumors with mediastinal, paravertebral, or thoracic
outlet involvement. Otherwise, in contradistinction to chon-
drosarcoma of the appendicular long bones, MRI oﬀers no
advantage over CT and is not a necessary part of a routine
radiologic evaluation. Positron emission tomography (PET)
with ﬂuorine-18 ﬂuorodeoxyglucose (FDG) is performed to
rule out extrapulmonary metastases. PET has also demon-
strated some utility in diﬀerentiating benign cartilaginous
tumors from chondrosarcoma. Furthermore, preoperative
PET imaging and comparison of standardized uptake value
(SUV)with histologic grademay predict postsurgical patient
outcome. In a retrospective review of 31 patients with
chondrosarcoma (25% with disease localized to the thorax),
the combination of pretherapeutic SUV and histopathologic
tumor grade allowed identiﬁcation of patients at high risk
for local relapse or metastatic disease [9]. Cross-sectional
brain imaging is reserved for patients with recent onset
of neurologic symptoms as intracranial metastasis from
primary chest wall neoplasms is rare.
Prior toentertaining major surgical resection, a complete
physiologic evaluation is performed, including pulmonary
function tests (PFTs) with spirometry. This exam is partic-
ularly important in patients in whom pulmonary resection
is anticipated, or in patients potentially requiring a largeSarcoma 3
Figure 2: Typical CT appearance of an anterior chest wall chon-
drosarcoma arising from the chondrosternal junction, demonstrat-
ing prominent chondroid matrix mineralization resulting in a
characteristic ﬂocculent or “popcorn” pattern of calciﬁcation [6].
anterior chest wall resection, as this tends to impede venti-
latory mechanics postoperatively. Further interrogation by
quantitative perfusion or exercise oximetry is required in
cases of questionable pulmonary reserve.
Previous teaching dictated that incisional biopsy be
performedroutinelyforallchestwallmasses.However,thisis
no longer the recommendation. Small single rib lesions can
be removed as a therapeutic excisional biopsy. A lobulated
mass with ﬂocculent calciﬁcation arising from the sternum
or costochondral junction is a chondrosarcoma until proven
otherwise and does not require preoperative diagnosis in a
suitable operative candidate. Benign chondroma and low-
gradechondrosarcoma are often histologicallyindistinguish-
able by preoperative biopsy, and therefore both are treated
by wide excision [2]. If the diagnosis is in question, percu-
taneous image-guided core needle biopsy and sophisticated
cytopathology techniques should yield a diagnosis in the
majority of cases [10]. In rare cases in which percutaneous
core biopsy is unsuccessful, a carefully placed incisional
biopsy is necessary. A small incision should be placed along
the long axis of the tumor with careful consideration given
for eventual removal of the area at deﬁnitive resection. The
wound should be closed in layers, including the capsule of
the tumor, to prevent tumor spillage into the surrounding
tissues.
5.SurgicalResectionand Reconstruction
There is no indication for neoadjuvant radiation or chem-
otherapy in a suitable surgical candidate with resectable
thoracic chondrosarcoma. Wide resection of all thoracic
disease with appropriatemargins, reconstruction of thebony
chest wall to ensure preservation of respiratory mechanics,
and soft-tissue coverage of reconstructive prostheses with
healthy, vascularized tissue is the treatment of choice. Pos-
terior tumors in the paravertebral region may demonstrate
involvement of vertebral bodies and/or neural foramina on
preoperative MRI. If so, preoperative neurosurgical consul-
tationisobtained inanticipation ofvertebrectomy. Similarly,
if large volumeorfree soft-tissue transfer with microvascular
anastomosis is anticipated, preoperative consultation with a
reconstructive surgeon may be of beneﬁt.
An epidural catheter is inserted preoperatively unless
there is concern for spinal involvement. Double-lumen oro-
tracheal intubation is utilized in every patient to allow
deﬂation of the ipsilateral lung. Lung deﬂation facilitates
wedge resection of adherent or involved lung and allows
careful palpation of uninvolved lung to identify unsuspected
metastasis.
Patient positioning and incision placement are dictated
primarily by the location of the lesion. Skin and soft-tissue
involvement by local tumor extension, previous irradiation,
or prior incisional biopsy must also be considered, as these
tissues should be resected en bloc and may indicate the need
for rotational or free tissue transfer. In general, patients with
sternal tumors are placed supine, and patients with anterior
tumors involving the costochondral junction are supine with
the ipsilateral thorax elevated 30–45◦. Patients with lateral
and posterior tumors are placed in the lateral decubitus
position as for standard posterolateral thoracotomy.
If overlying skin and subcutaneous tissues are unin-
volved, they are simply divided sharply to expose the under-
lyingchestwall musculature,which maybesparedordivided
if uninvolved by tumor. If the deep muscular fascia is
felt to be adherent to the tumor, the overlying area of
muscle should be resected en bloc with an appropriate
margin. If the extrathoracic musculature is to be spared for
later reconstruction, skin ﬂaps may be raised to facilitate
mobilization and retraction of the muscle for exposure. The
intercostal incision should be planned based on preoperative
imaging and palpation of the exterior surface of the mass,
so that the pleural space is entered one uninvolved rib
below the tumor. Upon entry into the pleural space, the
surgeon should palpate the tumor from within the chest
to further plan the resectionm a r g i n .T h eg r o s st u m o r -
free margin should include at least a portion of a normal
rib superiorly and inferiorly and at least 4cm anteriorly
and posteriorly. 1cm segments of each resected rib are
obtained anteriorly and posteriorly, individually labeled,
and submitted as ﬁnal pathologic margins following decal-
ciﬁcation. Posteriorly located tumors frequently require
disarticulation of the ribs from the transverse processes and
vertebral bodies, with ligation of the neurovascular bundles
as they exit the neural foramina. En bloc vertebral resection
and reconstruction occasionally necessitates neurosurgical
assistance. The specimen is oriented for the pathologist. Any
suspicious soft-tissue margins can be submitted for frozen
section analysis. The ipsilateral lung should be carefully
palpated for occult metastases, which should be resected
prior to commencement of reconstruction.
Chondrosarcoma of the sternum should also be resected
with at least a 4cm margin. This typically requires resection
o ft h ee n t i r eb o d yo ft h es t e r n u m .I ft h em a r g i ni sa d e q u a t e ,
partorallofthemanubriummaybepreservedandthestabil-
ityofthethoracicinletstructuresmaintained, facilitatingfull
range of motion and function at the shoulder. If resection of4 Sarcoma
the manubrium is required to achieve an adequate margin,
the clavicular heads are either disarticulated or resected en
bloc along with the ﬁrst costal cartilage. Sternal resection is
typically performed through a vertical midline skin incision.
The pectoralis major muscles are either reﬂected laterally or
resected en bloc where adherent to tumor. A retrosternal
plane is developed superiorly at the sternal notch (if total
sternectomy is anticipated) and inferiorly at the xiphoid
process. Segments of costal cartilage are resected at each
level and submitted for pathologic analysis as described
above. The intervening neurovascular bundles are ligated
and divided along with the intercostal muscles. The sternum
is then elevated using a bone hook, and the resection
is completed by incision of the posterior perichondrium
bilaterally.
Options for reconstruction of a bony thoracic defect are
numerous. Defects less than 5cm in diameter which do
not overly cardiac structures need not be reconstructed if
adequatesoft-tissue coverageexists. In general,large anterior
defects negatively impact respiratory mechanics greater
than posterolateral defects and therefore should be rigidly
reconstructed. Large defectsat the posteriorapex are covered
by the scapula and do not require reconstruction. However,
if the inferior resection margin includes the fourth rib, it
becomes possible for the scapular tip to fall into the pleural
s p a c ea n dc a t c hu n d e rt h es u p e r i o re d g eo ft h eﬁ f t hr i b
while in a normal postoperative anatomic position. This
creates a condition which is extremely painful and requires
reoperation to prevent further episodes. If this situation
appears likely, prosthetic reconstruction of the defect should
be undertaken. Defects larger than 5cm and those overlying
cardiac structures should be reconstructed. Both polypropy-
lene (Prolene or Marlex) mesh and polytetraﬂuoroethy-
lene (PTFE, Gore-Tex) have been successfully employed
for this purpose, and each material has its proponents.
With the exception of chest wall resection accompanying
pneumonectomy (for which we employ PTFE to achieve
a watertight pleural seal), we prefer polypropylene mesh.
The mesh provides a matrix for tissue ingrowth and has,
on occasion, been retained even when infected. While it
is less likely to engender an overlying seroma than PTFE,
its interstices ﬁll with ﬁbrin and leakage of pleural ﬂuid
is rarely a problem. Large anterior defects require rigid
reconstructionforpreservationofrespiratory mechanicsand
protection of underlying cardiac structures. Rigidity, when
indicated, is provided by creating a methyl methacrylate
“sandwich” consisting of a double sheet of polypropylene
mesh with a thin layer of methyl methacrylate paste spread
between. Prior to setting, the prosthesis can be contoured
appropriately by placing it over the patient’s thigh or ﬂank.
The polypropylene mesh is sewn to rib margins using heavy
polypropylene suture. Placement of sutures and avoidance
of intercostal nerve entrapment is facilitated by creation
of 1mm holes in the ribs using a hand-held pneumatic
or manual drill. The mesh should be pulled taught as the
sutures are inserted and tied to ensure sturdy reconstruction.
If overlying soft-tissue and musculature has been spared,
meticulous layered closure over a Blake drain is all that
is required. If the overlying chest wall musculature was
resected en bloc, skin and adipose tissue alone should not
be closed over the prosthesis. Rather, the thoracic surgeon or
a reconstructive surgical colleague should perform rotation
of a pedicled muscle ﬂap (latissimus, pectoralis, rectus
abdominis, and serratus) for coverage of the prosthesis prior
to skin closure. If full thickness chest wall, including skin,
has been resected, rotation of a pedicled myocutaneous ﬂap
or free microvascular muscle transfer with skin graft is
required. Figure 3containsintraoperativephotographstaken
duringresectionofananteriorthoracicchondrosarcomaand
subsequent reconstruction using polypropylene mesh and
methyl methacrylate.
Most patients can be extubated in the operating room
following chest wall resection, and empirical prolonged
intubation is not indicated. Properly reconstructed defects
should not impair respiratory mechanics too severely. Ade-
quate cough and avoidance of secretion retention are of the
utmost importance to prevent pneumonia and respiratory
failure. These are greatly facilitated by epidural analgesia.
However, aggressive pulmonary physiotherapy and toilet
bronchoscopy are sometimes required in the immediate
postoperative period.
Surgical Series. Due to their rarity, relatively few series of
primary chest wall tumors have been reported. Chondrosar-
coma is among the most frequently encountered tumor
types in most such series. A series of 110 patients treated
in Uniformed Services hospitals in Washington, DC was
reported in 1982. 46.4% had benign tumors, and 53.6%
had malignant primary chest wall neoplasms, of which
chondrosarcoma was the second most common. Patients
with chondrosarcoma had the highest 5-year survival (89%)
[11].
90 patients had chest wall resection for primary tumors
over a 20-year period at the Mayo Clinic. Approximately 2/3
of tumors originated in soft-tissue, while 1/3 originated in
boneorcartilage.Chondrosarcomaaccountedfor24%ofthe
entire series; moreover, it was the most common histologic
type of primary chest wall bone tumors (58.6%). Greater
than 50% of patients with malignant tumors developed
recurrence. 5-year recurrence-free survival was 56% in
patients with a 4cm resection margin, as compared to only
29% in patients with a 2cm margin. 5-year survival for
chondrosarcoma patients was 70%. Based on their ﬁndings,
the authors recommended a resection margin of 4cm of
normal tissue for all primary malignant chest wall tumors
[1].
In 1985, the Mayo group reported on their experience
with 96 patients with primary chondrosarcoma of the chest
wall. 81% arose in ribs and 19% in the sternum. 67%
arose anteriorly near the costochondral or chondrosternal
junction, and 25% arose posteriorly from the head of
the rib. Approximately 6% had metastatic disease at the
time of diagnosis. The 10-year disease-speciﬁc survival was
60.4%. Retrospective review of operative reports and gross
specimens was used to separate patients into groups who
underwent wide resection (2–4cm margins) and those who
underwent local excision only (minimal margin). 10-year
chondrosarcoma survival was 96.4% for those who hadSarcoma 5
(a) (b)
(c)
Figure 3: Intraoperative photographs taken during resection of an anterior thoracic chondrosarcoma and subsequent reconstruction using
polypropylene mesh and methyl methacrylate. The initial thoracotomy is created at least one rib below the level of palpable tumor (a).
Surgical specimen followingradicalexcision with adequate wide margins(b). Followingreconstruction ofthe right anteriorchest wallusing
polypropylene mesh and methyl methacrylate (c).
wide resection, compared with 65.4% for those who had
local excision only. Tumor diameter, grade, location, and
date of operation all signiﬁcantly aﬀected survival. Patients
with sternal tumors had improved 10-year survival (81.3%),
compared with patients with rib tumors (55.6%). Recurrent
chondrosarcoma developed in 52.1% of patients who under-
went initial surgical resection at Mayo. 62% recurred locally,
while 38% recurred both locally and systemically. Metastases
wereseentodevelopupto12yearsfollowingresection.Inter-
estingly, no patient developed systemic metastasis without
evidence of local recurrence. Indeed, local recurrence was
an ominous event, with 68% of patients recurring locally
ultimately dying of chondrosarcoma [7].
In 1992, the group at Memorial Sloan-Kettering Cancer
Center reported on their 40-year experience with pri-
mary bony and cartilaginous chest wall malignancies. 10%
of chondrosarcoma patients presented with synchronous
systemic metastases. Of 84 patients undergoing primary
resection for chondrosarcoma, 28% recurred locally as the
ﬁrst site of recurrence. Of 79 patient who presented with
local disease only, 18% eventually developedlung metastasis.
The overall 5-year survival for chondrosarcoma patients was
64%.Localrecurrence was seentoportend distant metastasis
in this series as well, with metastasis seen in only 4% of
patients with no local recurrence compared with 29% who
had recurred locally. The authors concluded that the single
most important factor predicting survival was completeness
of ﬁrst resection [3].
The group at M.D. Anderson Cancer Center presented
a 10-year review of 51 patients with primary chest wall
sarcomas [10]. Of the 51 patients, 9 required incisional
biopsy, with the remainder undergoing excisional biopsy,
needle biopsy, or deﬁnitive resection based on radiologic
appearance alone. 29% were chondrosarcomas. Histology
was the most signiﬁcant predictor of survival. 5-year sur-
vival for chondrosarcoma patients was 92.3%. Furthermore,
patients with sternal tumors fared better than those with
rib involvement, likely due to the higher proportion of
sternal chondrosarcomas. The authors stressed that they
avoid incisional and excisional biopsies, instead performing
needle biopsy if the diagnosis is in question or proceeding
with deﬁnitiveresection iftheradiographic diagnosisisclear.
Most recently, a report of 106 consecutive Swedish
thoracic chondrosarcoma patients over a 22-year period was
published by theScandinavian Sarcoma Group. In this study,
patients treated at orthopedic sarcoma centers were more6 Sarcoma
likely to be resected with wide surgical margins than those
treated at nonspecialty centers. Not surprisingly, this trans-
lated to decreased local recurrence and increased 10-year
survival for patients treated at specialty centers [12]. Similar
to the reported Mayo [7] and Memorial Sloan-Kettering
[3] series, inadequate initial resection margins portended
local recurrence, which portended systemic metastasis and
mortality.
6.PostoperativeSurveillance
Due to the possibility of late local and systemic recurrence,
resected patients should undergo routine lifelong surveil-
lance. Surveillance consists of physical examination and
thoracic imaging with either PA/lateral radiograph or CT
scan every 3–6 months for the ﬁrst 5 years and annually
thereafter for a minimum of 10 years.
7.LocalRecurrence
Despite wide local excision, local recurrence may occur in
up to 50% of patients with thoracic chondrosarcoma. High
tumor grade, inadequate margins at initial resection, and
resection at a nonspecialty center have been reported to
predict local recurrence [7, 12]. In operable patients in
whom reexcision with margins can be achieved, subsequent
resections are reasonable. Usually, local recurrence portends
systemic metastasis and poor outcome. However, in one
report, patients resected for local recurrence fared no
worse than patients presenting for initial resection [10].
Inoperable patients with local recurrence should be referred
for consideration of radiotherapy.
8.Radiotherapy
While chondrosarcoma is relatively radioresistant, conven-
tional radiation therapy has demonstrated eﬃcacy and
should be administered at sites of positive pathologic
margins (if a wider surgical margin cannot be achieved) or
in cases of unresectability [5]. Particle therapy with protons
and carbon ions has proven eﬃcacy in incompletely resected
chondrogenic tumors of the skull base [13, 14]. However,
there are no reports describing utilizationofthese modalities
for thoracic chondrosarcoma.
9.SystemicTherapy
Unfortunately, at present, there is no eﬀective systemic
cytotoxic chemotherapy for metastatic chondrosarcoma.
This resistance to therapy is most probably related to
several intrinsic biologic characteristics of these neoplasms,
among them abundance of chondroid matrix, low cellular
grade, and relative hypovascularity. Although prospective
data are lacking, variant subtypes such as dediﬀerentiated
and mesenchymal chondrosarcoma may be sensitive to
combination chemotherapy and may be considered for
adjuvant or palliative chemotherapy in the context of a
clinical trial [5].
10.LungMetastasis
As stated, approximately 5–10% of patients with primary
chondrosarcoma of the chest wall present with synchronous
pulmonary metastasis. Metachronous metastatic chon-
drosarcoma may present as a slowly enlarging pulmonary
nodule or as a pulmonary inﬁltrate which may be initially
confused as pneumonia [15]. Although pulmonary metasta-
sectomy for sarcomatous neoplasms has proven therapeutic
beneﬁt [16], there is a paucity of data regarding pulmonary
resection for metastatic chondrosarcoma in adults. Gen-
eral principles of pulmonary metastasectomy are similarly
applied irrespective of histologic origin. The primary tumor
should be controlled, and there should be no evidence
of extrathoracic metastatic disease. Furthermore, complete
resection of all intrathoracic disease should be technically
and physiologically possible, as debulking of pulmonary
metastases is of no beneﬁt. Unilateral lesions are generally
approachedviaaxillaryorposterolateralmuscle-sparingtho-
racotomy, which, as opposed to thoracoscopy, allow careful
palpation of the entire ispilateral lung to evaluate for further
metastases. Bilateral lesions may be approached via staged
thoracotomy, although median sternotomy or transverse
thoracosternotomy (clamshell incision) can be utilized in
some circumstances. Margin-negative wedge resection is the
preferred surgical option. Lobectomy or pneumonectomy
can be considered for deep lesions not amenable to wedge
resection.
11.Summary
Althougha rare entity,chondrosarcoma isthemost common
malignant tumor of the chest wall. Most patients present
with an enlarging, painful anterior chest wall mass. CT scan
is the gold standard radiographic study for diagnosis and
operative planning. Contrary to previous dictum, resection
maybeperformedinanappropriatesurgicalcandidatebased
on imaging characteristics or image-guided percutaneous
biopsy results; incisional biopsy is rarely required. The keys
to successful treatment are early recognition and radical
excision with adequate margins. Overall survival is excellent
in most surgical series from experienced centers. Complete
excision with widely negative microscopic margins at the
initial operation is of the utmost importance, as local
recurrenceportendssystemicmetastasisandeventualtumor-
related mortality.
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